Empromptu LogoEmpromptu

Start with one program. Reconcile dispensing, eligibility, and finance data; prove tightened compliance and protected sa
Our 340B savings are leaking to manufacturer restrictions an

You can pilot reconciliation across EHR/pharmacy/finance for one program without a TPA switch.

What changes when AI orchestration runs the loop

Not 'another 340B add-on' -> 'close the reconciliation gaps your TPA leaves exposed to clawback.'

You've got a TPA; the EHR/pharmacy/finance reconciliation gaps still drive audit risk. A model that reconciles across systems and assembles documentation closes the gap generic tools leave.

Not 'more split-billing rules' -> 'clear the reconciliation exceptions your platform can't.'

You've got split-billing software; exception reconciliation across fragmented data stays manual. A model trained on your reconciliation decisions clears the matches and flags real exceptions.

Not 'more rules' -> 'prove the controls operate, not just that rules exist.'

You apply rules; validating they work in practice is manual. A model trained on your control decisions evidences operation and assembles the HRSA-ready trail - so a CAP reflects real remediation.

Not 'more TPA logic' -> 'find why a claim was missed or wrongly captured, traced to source.'

You've got TPA reporting; diagnosing discrepancies across misaligned feeds is manual. A model trained on your data relationships traces each discrepancy to root cause across EHR/pharmacy/TPA.

Where the work changes

Five frames in this vertical's language — leak, operational, governance, analysis, growth.

Leak / value-capture: Not 'another 340B add-on' -> 'close the reconciliation gaps your TPA leaves expo

Our 340B savings are leaking to manufacturer restrictions and we're one audit gap from clawback.

  • Manufacturer contract-pharmacy restrictions erode savings; savings at risk industry-wide.
  • HRSA audit exposure for duplicate discounts, diversion, eligibility documentation.
  • Data-integration gaps between EHR, pharmacy dispensing, and finance create audit vulnerability.
  • Administrative strain as audit requests and reporting requirements increase.

Operational throughput: Not 'more split-billing rules' -> 'clear the reconciliation exceptions your plat

Every cycle we hand-reconcile 340B vs non-340B dispensing across systems that don't talk to each other.

  • Manual reconciliation across fragmented EHR / pharmacy / finance / wholesaler data each cycle.
  • Monthly/quarterly purchase-vs-dispense reconciliation is recurring high-volume throughput work.
  • Fragmentation + manual workflows drive the compliance-exception load (duplicate discount, diversion).
  • Audit-ready trail must be assembled by hand from disconnected systems.

Governance & audit: Not 'more rules' -> 'prove the controls operate, not just that rules exist.'

An unannounced HRSA audit can demand proof my duplicate-discount and diversion controls work, and I can't produce a validated, current trail.

  • HRSA audits (~200 covered entities/yr) demand validated internal controls against duplicate discount & diversion.
  • Adverse findings -> mandatory repayment to manufacturers; in extreme cases program removal.
  • Findings driven by documentation gaps, outdated policies, and controls 'not validated in practice.'
  • Filing a CAP without genuine remediation leads to re-audit failure.

Analysis / diagnosis: Not 'more TPA logic' -> 'find why a claim was missed or wrongly captured, traced

My true 340B capture is hidden in discrepancies between TPA feeds, EHR, and pharmacy data that interpret eligibility differently - diagnosing why a claim was missed or wrongly captured means tracing i

  • Multiple TPAs apply different logic and inconsistent data feeds - causing both missed eligible claims and false inclusions.
  • Diagnosing the true capture rate means comparing total claims processed vs those captured under 340B, across sources.
  • Misaligned systems produce discrepancies that are hard to trace to root cause.
  • Under the 2026 rebate model, every claim-level discrepancy is financially consequential (denials, repayment).

Where current tooling falls short

Category limitation: TPAs and split-billing tools handle qualification mechanics but reconciliation across fragmented EHR/pharmacy/finance data - the root of audit failures - remains weak; compliance judgment and documentation assembly stay labor-bound under rising audit volume.

Third-Party Administrators (TPAs) and split-billing/complian logo
Apexus-aligned tools logo
Verity/SUNRx-type TPAs) logo
EHR + pharmacy dispensing systems logo

What's leaking and what it costs

[SCENARIO-LABEL] ['~$3.2B/yr collective loss to manufacturer 340B restrictions; up to $8.4B in savings at risk (industry estimates, 2025).', '~18% of HRSA audits required repayments for duplicate-discount/diversion; ~4% required contract-pharmacy terminations tied to OPAIS errors
[SCENARIO-LABEL] ['Reconciliation runs on a monthly/quarterly purchase-vs-dispense cycle across fragmented systems (GATP 2025).', 'Duplicate discount and diversion each = 17% of HRSA audit findings, most tied to contract-pharmacy activity (GATP 2025).']
['HRSA audits ~200 covered entities/yr; adverse duplicate-discount/diversion findings can require repayment to manufacturers or program removal (HRSA; AHA 2025; Virtue340B 2026).', 'FY2024 findings: incorrect OPAIS ~50-62%, duplicate discount & diversion ~17% each (GATP 2025); 68
["Multiple TPAs 'apply different logic and use inconsistent data feeds,' causing missed eligible claims and false inclusions affecting millions in savings (Virtue340B 2026).", 'Diagnostic practice: compare total claims processed vs captured under 340B to find true capture rate; m

Frequently asked

Still have questions?

Book a 25-min call

An unannounced HRSA audit can demand proof my duplicate-discount and diversion controls work, and I can't produce a validated, current trail. Not 'more rules' -> 'prove the controls operate, not just that rules exist.'

Walk the numbers together